Specifically, in a cross-sectional study, we compared anti-IFI16 antibody levels of SLE patients at various stages of disease with those of patients with non-SLE primary glomerulonephritis (GN) or healthy individuals. This evidence concerns the gene IFI16 and ganglioneuroma.